Science and technology have always been a powerful dynamic in regeneration, and the fourth industrial revolution has many parallels with the first in the way that it ...

Looking back, the 1983 Orphan Drug Act was a pivotal moment for healthcare, not just in the US but worldwide too. Research on orphan diseases has since flourished, pa...

There has been an unprecedented shift in global demographics, as the human population becomes more aged. This is bringing with it a significant burden of age-related ...

Interest in the microbiome continues to grow at a robust rate, underlying its potential to significantly benefit human health. In part 1 of this series, the role of t...

Oligonucleotides’ ability to inhibit genes or to function as aptamers to interact with protein targets are increasingly vital research tools in the biopharmaceutical ...

Although rare diseases, by definition, affect fewer individuals than other diseases do, they tend to be particularly devastating: they are often debilitating or letha...

Over the past five years, we have seen remarkable growth and clinical results in an area of medicine known as advanced therapy medicinal products (ATMPs), which compr...

The New Drugs and Clinical Trial Rules (NDTC), 2019 were recently issued, emphasising the changes on the regulatory aspects relating to clinical trials. The final doc...

CAR-T therapies are set to revolutionise cancer treatment. With first curative therapies gaining market access across the globe, CAR-T therapies are subject to numero...

Epilepsy is a debilitating illness which impacts the life of millions of people across the world. Tony Hitchcock of Cobra Biologics discusses how Cobra Biologics and ...